Iranian Journal of Microbiology 2010. 2(3):120-127.

Antibody against recombinant heat labile enterotoxin B subunit (rLTB) could block LT binding to ganglioside M1 receptor
J Salimian, AH Salmanian, R Khalesi, M Mohseni, SM Moazzeni


Objectives: Enterotoxigenic Escherichia coli (ETEC) is one of the most common agents of diarrhea among other bacterial agents. Designing and producing vaccine against these bacteria is one of the major purposes of World Health Organization (WHO). Due to presence of diverse clones of ETEC strains in the world, the use of global vaccines for ETEC infection is controversial. B subunit of heat labile toxin (LTB) was introduced as a vaccine candidate molecule by several investigators. The expression of LTB gene isolated from a local bacterial strain and investigation of its immunological property was the objective of this study.
Materials and Methods: LTB gene was isolated from a local isolated ETEC, cloned and expressed using pET28a expression vector. For LTB gene expression, the three main expression parameters (IPTG concentration, time and temperature of induction) were investigated. The recombinant protein was purified ( > 95%) with Ni-NTA column using 6XHis-tag and used as an antigen in ELISA test.
Results: The immunological analyses showed production of high titer of specific antibody in immunized mice. Anti LTB Antibody could bind to whole toxin and neutralize the toxin through inhibition of its binding to the Ganglioside M1 receptor.
Conclusion: The recombinant LTB protein is a highly immunogenic molecule. Considering the LTB role in ETEC pathogenesis, it can be taken into account as one of the most important components of vaccines against local ETEC.


Enterotoxigenic Escherichia coli (ETEC); Heat Labile Enterotoxin B Subunit (LTB); Recombinant Vaccine; GM1 Receptor Assay

Full Text:



Guerrant RL, Kosek M, Moore S, Magnitude and Impact of Diarrheal Disease. Arch Med Res 2002; 33:351-355.

Jafari F, Garcia-Gil LJ, Zali MR. Diagnosis and prevalence of enteropathogenic bacteria in children less than 5 years of age with acute diarrhea in Tehran children’s hospitals. J Infect 2009; 58: 21-27.

Jafari F, Shokrzadeh- Ahrabi L, Hamidian M, Salmanzadeh S, Zali MR. Acute diarrhea to Enterotoxigenic bacteria in patients at hospital in tehran.Jpn J Infect Dis 2008; 61: 269-273.

Wenneras C, Erling V. Prevalence of Enterotoxigenic Escherichia coli associated Diarrhea and Carrier State in the Developing World. J Health Popul Nutr 2004;22: 370-382.

Stauffer WM, Konop R.J, Kamat D.Travelling with infants and young children. Part III: Travellers diarrhea. J Travel Med 2002; 9: 141-150.

Steffen R, De Bernardis C, Banos A, Travel epidemiology-a global perspective. Int J Antimicrob Agents 2003; 21: 89-95.

Qadri F, Svennerholm AM, Faruque ASG, Bradley Sack R. Enterotoxigenic Escherichia coli in Developing Countries: Epidemiology, Microbiology, Clinical Features, Treatment, and Prevention. Clin Microbiol Rev 2005; 18: 465-483.

Walker RI, Steele D, Aguado T. Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. coli (ETEC) disease. Vaccine 2007; 25: 2545-2566.

Svennerholm AM, Tobias J. Vaccines against entero- toxigenic Escherichia coli. Vaccine 2008; 7: 795-804.

Sanchez J, Holmgren J. Virulence Factors, Pathogenesis and Vaccine Protection in Cholera and ETEC Diarrhea. Curr Opin Immunol 2005; 17: 388- 398.

Millar DG, Hirst TR, Snider DP. Escherichia coli heat-labile enterotoxin B subunit is a more potent mucosal adjuvant than its closely related homologue, the B subunit of cholera toxin. Infect Immun 2001; 65:3476-3482.

Fleckenstein JM, Hardwidge PR, Munson GP, Rasko DA, Sommerfelt H, Steinsland H. Molecular mechanisms of enterotoxigenic Escherichia coli infection. Microbes Infect 2010; 12: 89-98.

Shaheen H I, Abdel Messih IA, Klena J D, Mansour A, Svennerholm A M. Phenotypic and Genotypic Analysis of Enterotoxigenic Escherichia coli in samples obtained from egyptian children Presenting to referral hospitals. J Clin Microbiol 2009; 47: 189-197.

Sambrook J, Russell DW. Molecular Cloning: A Laboratory Manual. 3rd edition. New York: CSHL PRESS; 2001.

Bollag DM, Michel DR, Edelstein SJ. Protein Methods. 2nd edition. 1996.Wiley-Liss, New York. pp 50-55. pp. 96-127.

Wingfield P.T, Palmer I,Liang SM. Folding and purification of insoluble (inclusion-body) proteins from Escherichia coli. Current protocols in protein science 1995; 1: 6.5.1-6.5.27.

Kunkel SL, Robertson DC. Purification and chemical charcterization of the heat-labile enterotoxin produced by enterotoxigenic Escherichia coli. Infect Immun 1979; 25: 586-596.

Menezes CA, Imamura SY, Trabulsi LR, Fernandes- Filho A, Martinez MB. Production, characterization, and application of antibodies against heat-labile type-I toxin for detection of enterotoxigenic Escherichia coli. Mem Inst Oswaldo Cruz Rio de Janeiro 2006;101: 875-880.

Svenerholm AM, Wiklund G. Rapid GM1-enzyme- linked immunosorbent assay with visual reading for identification of Escherichia coli heat-Labile enterotoxin. J Clin Microbiol 1983; 17: 596-600.

Ma X, Zheng W, Wang T, Wei1 D, Ma Y. Optimization and high-level expression of a functional GST-tagged rHLT-B in Escherichia coli and GM1 binding ability of purified rHLT-B. J Microbiol 2006; 44: 293-300.

Kiyono H, Yuki Y, Tokuhara D, Nochi T, Yasuda H, Mejima M, Kurokawa S. Oral MucoRice expressing double-mutant cholera toxin A and B subunits induces toxin-specific neutralising immunity. Vaccine 2009;27: 5982-5988.

McKenzie R, Bourgeois A. L, Frech S. A, Flyer DC, Bloom A, Kazempour K, Glenn GM, Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): Protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine 2007; 25: 3684-3691.

Glenn GM, Villar CP, Flyer DC, Bourgeois AL, McKenzie R, Lavker RM, Frech SA. Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum. Infect Immun 2007; 75(5): 2163-217.

Yamamoto T, Yokota T, Kaji A. Molecular organization of heat-labile entrotoxin genes originating in Escherichia coli of human origin and construction of heat-labile toxoid-producing strains. J Bacteriol 1981;178: 983-987.

Yan J, Wang Y, Shao SH, Mao YF, Li HW, Luo YH. Construction of prokaryotic expression system of LTBUreb fusion gene and identification of the recombinant protein immunity and adjuvanticity. World J Gastroenterol. 2004; 10: 2675-9.

Hajishengallis G, Arce S, Gockel CM, Connell TD, Russell MW. Immunomodulation with Enterotoxins for the Generation of Secretory Immunity or Tolerance: Applications for Oral Infections. J Dent Res 2005; 84:1104-1116.

De Mattos Areas AP, Sarno de Oliveira ML, Ramos CR, Sbrogio-Almeida ME, Raw I, Ho PL. Synthesis of cholera toxin B subunitgene: cloning and expression of a functional 6 his-tagged protein in Escherichia coli. Protein Express Purif 2002; 25: 481-7.

Rezaee MA, Rezaee A, Moazzeni SM, Salmanian AH, Yasuda Y, Tochikubo K, Pirayeh SN, Arzanlou M.Expression of Escherichia coli heat-labile enterotoxin B subunit (LTB) in Saccharomyces cerevisiae. J Microbiol 2005; 43(4): 354-60.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.